The Future of Regenerative Medicine
Celltex Therapeutics is a Houston-based biotechnology company specializing in banking one’s own mesenchymal stem cells, often called MSCs, for therapeutic use.
Celltex’s proprietary stem cell processing and banking methods ensure the genetic integrity and uniformity of an individual’s cells in quantities never before possible and in the quantities necessary for therapeutic applications. An individual can then use his or her banked stem cells for regenerative therapy through infusions or injections performed by a licensed physician in Cancun.
Celltex Therapeutics Corporation was founded in 2011 by David Eller and internationally known spine surgeon Dr. Stanley Jones to spearhead breakthroughs in regenerative medicine through adult stem cells. Celltex uses proprietary technology that isolates, multiplies and stores autologous, adult, adipose (fat tissue)-derived mesenchymal stem cells (MSCs) to be used for regenerative therapy in a number of conditions, including vascular, autoimmune and degenerative diseases.
Jones was determined to bring this technology to the United States after suffering debilitating autoimmune arthritis that rendered him unable to perform surgery and threatened to end his career. He traveled to Asia in 2010 and 2011 to receive regenerative therapy using his own stem cells. Where conventional treatments failed to resolve his symptoms, stem cell therapy brought relief. Within four months of receiving his own stem cells, Jones was able to return to his surgical practice. MSCs have been, and continue to be, used in many countries, so in 2011, Eller and Jones founded Celltex to bring the potential of stem cell therapy to the United States.
Today, Celltex Therapeutics Corporation remains committed to leading the United States into the future of regenerative medicine through adult stem cells. Its industry leadership and visionary approach continue to drive the company to improve the quality of life of thousands of individuals, with a concerted focus to make this therapy accessible to all in the near future.